

# Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

GBD 2016 Lower Respiratory Infections Collaborators\*



## Summary

**Background** Lower respiratory infections are a leading cause of morbidity and mortality around the world. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016, provides an up-to-date analysis of the burden of lower respiratory infections in 195 countries. This study assesses cases, deaths, and aetiologies spanning the past 26 years and shows how the burden of lower respiratory infection has changed in people of all ages.

**Methods** We used three separate modelling strategies for lower respiratory infections in GBD 2016: a Bayesian hierarchical ensemble modelling platform (Cause of Death Ensemble model), which uses vital registration, verbal autopsy data, and surveillance system data to predict mortality due to lower respiratory infections; a compartmental meta-regression tool (DisMod-MR), which uses scientific literature, population representative surveys, and health-care data to predict incidence, prevalence, and mortality; and modelling of counterfactual estimates of the population attributable fraction of lower respiratory infection episodes due to *Streptococcus pneumoniae*, *Haemophilus influenzae* type b, influenza, and respiratory syncytial virus. We calculated each modelled estimate for each age, sex, year, and location. We modelled the exposure level in a population for a given risk factor using DisMod-MR and a spatio-temporal Gaussian process regression, and assessed the effectiveness of targeted interventions for each risk factor in children younger than 5 years. We also did a decomposition analysis of the change in LRI deaths from 2000–16 using the risk factors associated with LRI in GBD 2016.

**Findings** In 2016, lower respiratory infections caused 652 572 deaths (95% uncertainty interval [UI] 586 475–720 612) in children younger than 5 years (under-5s), 1 080 958 deaths (943 749–1 170 638) in adults older than 70 years, and 2 377 697 deaths (2 145 584–2 512 809) in people of all ages, worldwide. *Streptococcus pneumoniae* was the leading cause of lower respiratory infection morbidity and mortality globally, contributing to more deaths than all other aetiologies combined in 2016 (1 189 937 deaths, 95% UI 690 445–1 770 660). Childhood wasting remains the leading risk factor for lower respiratory infection mortality among children younger than 5 years, responsible for 61·4% of lower respiratory infection deaths in 2016 (95% UI 45·7–69·6). Interventions to improve wasting, household air pollution, ambient particulate matter pollution, and expanded antibiotic use could avert one under-5 death due to lower respiratory infection for every 4000 children treated in the countries with the highest lower respiratory infection burden.

**Interpretation** Our findings show substantial progress in the reduction of lower respiratory infection burden, but this progress has not been equal across locations, has been driven by decreases in several primary risk factors, and might require more effort among elderly adults. By highlighting regions and populations with the highest burden, and the risk factors that could have the greatest effect, funders, policy makers, and programme implementers can more effectively reduce lower respiratory infections among the world's most susceptible populations.

**Funding** Bill & Melinda Gates Foundation.

**Copyright** © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

## Introduction

Lower respiratory tract infections, defined in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) as pneumonia or bronchiolitis, are a leading cause of mortality and morbidity worldwide. Nearly 2·38 million deaths resulted from lower respiratory infections in 2016, making lower respiratory infections the sixth leading cause of mortality for all ages and the leading cause of death among children younger than

5 years.<sup>1</sup> Historically, lower respiratory infection burden varies substantially across the globe, disproportionately affecting the young and the impoverished.<sup>2</sup> People at highest risk for contracting or dying from lower respiratory infections often come from households with inconsistent or insufficient access to adequate nutrition, clean cooking fuel, vaccines, and sanitation, or have immunocompromising conditions.<sup>3</sup> Although there has been a substantial decrease in lower respiratory infection

*Lancet Infect Dis* 2018

Published Online  
September 19, 2018  
[http://dx.doi.org/10.1016/S1473-3099\(18\)30310-4](http://dx.doi.org/10.1016/S1473-3099(18)30310-4)

See Online/Comment  
[http://dx.doi.org/10.1016/S1473-3099\(18\)30407-9](http://dx.doi.org/10.1016/S1473-3099(18)30407-9)

\*Collaborators listed at end of Article

Correspondence to:  
Dr Robert C Reiner Jr, Institute for Health Metrics and Evaluation, Seattle, WA 98121, USA  
[rbcreiner@uw.edu](mailto:rbcreiner@uw.edu)

### Research in context

#### Evidence before this study

Lower respiratory infections are responsible for a substantial number of deaths, particularly among children younger than 5 years (under-5). Most other studies that have attempted to quantify the burden of lower respiratory infections have focused on children younger than 5 years or on subpopulations, such as immunocompromised children and adults. Other studies have attempted to quantify respiratory pathogens, such as *Streptococcus pneumoniae* or influenza, and have found a wide range of results depending on modelling assumptions and input data. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2015, showed lower respiratory infections being responsible for over 2.74 million deaths (95% uncertainty interval [UI] 2.50–2.86) in 2015, and the third leading cause of under-5 mortality worldwide. Furthermore, an estimated 291.8 million episodes (276.3–307.0) of lower respiratory infections occurred in 2015, and were the second leading cause of disability-adjusted life-years (103 million DALYs; 95% UI 96.1–109.1).

#### Added value of this study

This GBD analysis includes new data sources, new covariates, and various advances in the modelling methods. Furthermore, we produce estimates of hospitalisations due to lower respiratory infection (for all ages), highlight the underappreciated and growing burden of lower respiratory infections on elderly populations, and do a novel analysis of the effect of changes in risk factors over time on the lower respiratory infection mortality rate, allowing for targeted strategies unique to each location to reduce lower respiratory infection risk and mortality.

#### Implications of all the available evidence

The epidemiology of lower respiratory infections is changing, and large reductions in lower respiratory infection mortality, particularly among young children have occurred in the past 16 years. Still, air pollution, childhood undernutrition, and access to timely and appropriate health care represent challenges and opportunities for continuing to avert mortality due to this preventable cause of death.

mortality since 1990 (23.0% decrease, 95% uncertainty interval [UI] 15.7–29.4),<sup>1</sup> the majority of the remaining deaths could be avertable and require increased global investment in prevention and treatment interventions.

A handful of global initiatives have been developed to combat lower respiratory infections and other common illnesses, including the Global Action Plan for Pneumonia and Diarrhoea (GAPPD), Every Breath Counts, and the Stop Pneumonia Initiative. The GAPPD, created by WHO and UNICEF in 2013, is a global initiative focusing on the prevention and treatment of lower respiratory infections.<sup>4</sup> Among other initiatives, the GAPPD promotes interventions to address the most evident risks for contracting and dying from lower respiratory infections. It aims to reduce the burden of lower respiratory infection in every country by 2025, by lowering mortality to three deaths per 1000 people and lower respiratory infection incidence to 75% of the country-specific levels in 2010. Such goals were developed with an emphasis on childhood mortality and the substantial burden of lower respiratory infections among adults might not be fully appreciated. Understanding and quantifying trends in lower respiratory infection burden among people of all ages is crucial to develop plans that accelerate improvement and to provide timely and appropriate investment in interventions to reduce lower respiratory infection burden and to track progress toward global goals.

Estimates of the burden of lower respiratory infections and their aetiologies are produced annually as part of the GBD Study. This paper presents the results of GBD 2016 for lower respiratory infections and four high-burden aetiologies (*Haemophilus influenza* type b [Hib],

*Streptococcus pneumoniae*, influenza, and respiratory syncytial virus [RSV]), including deaths, episodes, disability-adjusted life-years (DALYs), and risk factors, the relationship between lower respiratory infections and social development, and intervention strategies for 195 countries, from 1990 to 2016, by age, for men and women. We build on previous descriptions of the global burden of lower respiratory infection by incorporating more than 287 000 additional cause of death and non-fatal datapoints. Further, this study provides greater emphasis on exploring the trends in morbidity and mortality, such as the relationships between cases and fatality, by highlighting the burden across all ages, and by identifying risks and interventions that have the greatest potential to reduce lower respiratory infection disease burden.

## Methods

### Overview

Detailed methods for the GBD study and on lower respiratory infection estimation in GBD have been previously published.<sup>1,5</sup> We describe these methods briefly, focusing on changes from previous GBD methods. There were no substantial modelling changes between GBD 2015 and GBD 2016. Lower respiratory infections are defined as diseases of the lower airways, including pneumonia and bronchiolitis. Uncertainty in the lower respiratory infection estimates are maintained through the modelling process using draws, and are reflected as the 2.5 and 97.5 percentiles of the distribution. In compliance with the Guidelines for Accurate and Transparent Health Estimates Reporting,<sup>6</sup> data and code for the GBD 2016 cycle will be made

publicly available. The appendix shows more information about the data included in this study (pp 3–5, 9–13).

## Modelling

We modelled lower respiratory infection mortality using the Cause of Death Ensemble model (CODEm) platform. CODEm is a Bayesian, hierarchical, space-time, ensemble model designed to predict cause-specific mortality by age, sex, location, and year.<sup>17</sup> CODEm produces a wide variety of submodels designed to explore a diverse set of covariates (eg, childhood undernutrition, air pollution, and Socio-demographic Index) and model types. We added several new covariates for GBD 2016, including prevalence of childhood wasting (low weight-for-height) and underweight (low weight-for-age), vitamin A deficiency, zinc deficiency, health-care access and quality, and safe handwashing. A full list of covariates used in the CODEm modelling can be found in the appendix (pp 7–8). Each submodel is weighted on the basis of out-of-sample predictive validity, and contributes to a final set of 1000 draws that is composed of draws sampled from the submodels based on each model's statistical performance. These predictive regression models produce estimates of lower respiratory infection mortality for age, sex, location, and year on the basis of vital registration, verbal autopsy data, and surveillance system data.

The GBD 2016 used more than 30 000 datapoints from more than 700 sources. Compared with the GBD 2015, the GBD 2016 cycle expanded its data sources by adding 169 country-years of vital registration and 24 new verbal autopsy studies, including Sample Registration System data from the Government of India for each state, stratified by urban or rural residence.<sup>1</sup> Detailed information about the International Classification of Disease (ICD) codes that were used to identify lower respiratory infections is available in the appendix (p 3). To ensure consistency and interpretability across GBD cause-specific estimations, we adjusted the sum of the all-cause-specific mortality estimates to equal the all-cause mortality estimate. We did this using CoDCorrect, in which the modelled values for lower respiratory infection and all other causes of mortality were scaled on the basis of the uncertainty of those values. A new process in GBD 2016 reassigned some lower respiratory infection deaths for which the underlying cause of death was because of disorders in elderly adults, such as Alzheimer's disease and Parkinson's disease, reducing the number of deaths among people aged 65 years and older.<sup>1</sup> This reassignment was based on the prevalence and mortality of those diseases for each location, year, sex, and people older than 65 years, and was designed to correct for systematic under-reporting of dementias as the underlying cause of death in the ICD death registry data.

We modelled lower respiratory infection incidence in DisMod-MR version 2.1 (DisMod). DisMod is a Bayesian, hierarchical meta-regression tool.<sup>8</sup> Similar to CODEm,

DisMod uses space-time information and country-level covariates to produce modelled estimates for each age, year, location, and sex. DisMod also contains a compartmental model that enforces a consistent relationship between incidence, prevalence, and mortality in a series of ordinary differential equations. Input data for these models include scientific literature, population representative surveys, and hospital and health-care utilisation records. We also modelled hospital admissions due to lower respiratory infection in DisMod using inpatient records exclusively. We expanded the database for lower respiratory infection modelling in the 2016 cycle to include 133 of these new sources and 9844 new datapoints by updating our systematic review from Jan 1, 2016, to May 31, 2017. Because lower respiratory infection is seasonal in many places, we introduced a method to adjust for data sources that were shorter than a year by fitting a sine and cosine model with a period of 6 months for each GBD region and adjusting the lower respiratory infection prevalence on the basis of the predicted deviation from the mean. More information on this process can be found in the appendix (pp 14–18).

We attributed lower respiratory infection episodes and deaths to four aetiologies: *S pneumoniae* (pneumococcal pneumonia), Hib, influenza, and RSV, which were identified by expert review for GBD 2010 on the basis of the aetiological burden and the available data. Aetiologies were estimated population attributable fractions (PAFs), which represent the proportional reduction in lower respiratory infection morbidity or mortality that would be observed if the exposure to the pathogen was zero. Aetiological attribution, based on counterfactual estimates, accounted for co-infection between pathogens and for the distribution of pathogens in healthy individuals. Our counterfactual approach to aetiological distribution allowed for co-attribution between aetiologies, and so PAFs do not sum to 100%. We did not attribute aetiologies to neonatal lower respiratory infection cases or deaths because of an absence of reliable data in this age group, and we did not consider Hib in age groups older than 5 years old because there were no data on vaccine effectiveness for the Hib vaccine in children older than 5 years.

## Aetiological attribution

We used a vaccine probe design to estimate the PAF for pneumococcal pneumonia and Hib by first calculating the ratio of vaccine effectiveness against non-specific pneumonia to pathogen-specific pneumonia at the study level.<sup>9–11</sup> We then adjusted this estimate by vaccine coverage, and for pneumococcal pneumonia we adjusted for the proportion of pneumococcal serotypes covered by the pneumococcal conjugate vaccine (ten-valent and 13-valent), and vaccine effectiveness to estimate country-specific and year-specific PAF values.<sup>12,13</sup> A detailed explanation of these calculations is provided in the appendix (pp 23, 24). We did not account for

See Online for appendix

For more on the GBD 2016 data and code see <https://ghdx.healthdata.org/>

herd immunity in our estimates. We used separate pneumococcal pneumonia and Hib age distributions, modelled in DisMod, to determine the PAF by age. Finally, we estimated PAFs for location and year using vaccine coverage modelled estimates.

We estimated the PAF for influenza and respiratory syncytial virus by calculating an attributable fraction using the following equation:

$$\text{PAF} = \text{Proportion} \times \left(1 - \frac{1}{\text{OR}}\right)$$

where OR is the odds ratio of lower respiratory infection given pathogen detection<sup>14</sup> and Proportion is the percentage of lower respiratory infection episodes that test positive for influenza (A and B) or RSV.<sup>15</sup> We used both PCR and non-PCR diagnostic data, and adjusted the non-PCR data to be comparable with the PCR data in the modelling process (appendix pp 29, 30). We updated a systematic literature review to include all data from GBD 2015 and for papers published between Jan 1, 2015, and Dec 31, 2016, and used DisMod to model the proportion of lower respiratory infection cases that are positive for influenza and RSV, separately, by location, year, age, and sex. Because the case fatality ratio for viral lower respiratory infection is lower than for bacterial lower respiratory infection, we determined a scalar of this relationship and adjusted the PAFs accordingly (appendix pp 27–30).

#### Risk factor attribution and decomposition

Methods for risk factor attribution to lower respiratory infection are described in detail elsewhere.<sup>16,17</sup> Briefly, risk factors also followed a PAF counterfactual approach, in which we modelled the prevalence of exposure using scientific literature and population representative surveys, and we modelled the relative risk of lower respiratory infection given exposure to that risk factor using published meta-analyses. We modelled the exposure level in a population for a given risk factor using DisMod and a spatiotemporal Gaussian process regression, depending on the risk factor.

To assess the effectiveness of targeted interventions for each risk factor among children younger than 5 years, we took advantage of the counterfactual definition of risk factor burden such that the lower respiratory infection mortality rate due to each risk factor was equivalent to the reduction expected in the complete absence of the risk factor. The number needed to treat is an epidemiological concept in which the rate of disease in two populations is compared.<sup>18</sup> Since the counterfactual rate of disease is simply the difference between the lower respiratory infection mortality rate and the mortality rate due to the risk factor, the number needed to treat is the inverse of the lower respiratory infection mortality rate due to that risk factor (ie, the difference between the observed and counterfactual lower respiratory infection mortality rate

in the absence of the risk factor). We did a decomposition analysis of the change in lower respiratory infection deaths from 2000–16 using the 12 risk factors associated with lower respiratory infection in GBD 2016. We chose this time period to show recent changes. We decomposed each risk factor independently; the decomposition assessed the change in lower respiratory infection mortality due to the risk factor, population growth, population ageing, and any remaining unexplained change in the lower respiratory infection mortality rate. This assumed independence overlooks well known correlation between risk factors. A combinatorial process determined the relative contribution of each component to the change in lower respiratory infection DALYs.<sup>5,16,19</sup> We did not incorporate uncertainty into our risk factor decomposition.

#### Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

#### Results

We estimated that in 2016, lower respiratory infections were a leading infectious cause of mortality worldwide in children younger than 5 years (under-5; 652 572 deaths, 95% UI 586 475–720 612), in adults older than 70 years (1080 958 deaths, 943 749–1 170 638), and in people of all ages (2 377 697 deaths, 2 145 584–2 512 809; table 1). In 2016, lower respiratory infections caused 13·1% of all deaths in children younger than 5 years (95% UI 11·8–14·3) and 4·4% of all deaths in people of all ages (95% UI 3·9–4·6). Most of the deaths due to lower respiratory infection in children younger than 5 years occurred in the first year of life (491 900 deaths, 95% UI 444 000–541 400). Among children younger than 5 years, we estimated that there were 68·06 million episodes (95% UI 55·29–82·72) in 2016, equivalent to 0·11 cases per child-year (95% UI 0·09–0·13; table 1). We estimated there were 5 133 000 hospital admissions because of lower respiratory infections in 2016, among children younger than 5 years (95% UI 3 860 800–6 260 200), and 65 982 807 hospital admissions due to lower respiratory infections among all ages 56 813 819–75 511 038). The highest incidence of lower respiratory infection episodes among children younger than 5 years occurred in Oceania (171·5 per 1000 children, 95% UI 132·2–217·9; table 1) and the greatest number of lower respiratory infection episodes among children younger than 5 years occurred in south Asia (18·76 million [95% UI 15·58–22·04]). For people of all ages, we estimated that there were 336·46 million episodes of lower respiratory infection (95% UI 313·08–361·62) in 2016 (table 1). Lower respiratory infections were responsible for 56 107 300 DALYs (95% UI 50 447 100–61 890 000) among


	Children younger than 5 years					Adults older than 70 years				
	Deaths (95% UI)	Deaths per 100 000 people (95% UI)	Millions of episodes (95% UI)	Episodes per 1000 people (95% UI)	Deaths (95% UI)	Deaths per 100 000 people (95% UI)	Millions of episodes (95% UI)	Episodes per 1000 people (95% UI)	Deaths (95% UI)	Deaths per 100 000 people (95% UI)
Global	2 377 697 (2 145 584–2 512 809)	32.2 (29.0–34.0)	336 46 (313 08–361 62)	45.5 (42.4–48.9)	652 572 (586 475–720 612)	103.3 (92.8–114.0)	68 06 (55 29–82 72)	107.7 (87.5–130.9)	1 080 958 (943 749–1 170 638)	267.4 (233.4–289.6)
High income	392 940 (362 375–425 101)	37.0 (34.1–40.0)	38 13 (35 84–40 52)	35.9 (33.8–38.2)	1905 (1749–2105)	3.3 (3.0–3.6)	2.58 (2.05–3.25)	44.6 (35.5–56.3)	337 271 (307 354–367 534)	252.5 (230.1–275.1)
High-income North America	105 127 (98 114–112 332)	29.3 (27.3–31.3)	13 93 (13 12–14 73)	38.8 (36.5–41.0)	669 (613–730)	3.1 (2.8–3.4)	1.19 (0.97–1.46)	55.1 (44.8–67.5)	81 270 (74 817–87 883)	227.6 (209.6–246.2)
Australasia	5164 (4532–5848)	18.0 (15.8–20.4)	1.26 (1.17–1.36)	43.9 (40.7–47.5)	36 (30–44)	2.0 (1.7–2.5)	0.11 (0.08–0.14)	60.5 (46.4–77.8)	4623 (3999–5305)	161.8 (140.0–185.6)
High-income Asia Pacific	109 683 (98 788–121 621)	60.8 (54.8–67.4)	8.12 (7.56–8.73)	45.0 (41.9–48.4)	194 (171–220)	2.6 (2.3–3.0)	0.48 (0.36–0.62)	64.6 (48.9–84.8)	100 501 (90 040–112 207)	337.2 (302.1–376.4)
Western Europe	138 945 (126 055–152 808)	32.4 (29.4–35.7)	12 28 (11 47–13 20)	28.7 (26.8–30.8)	379 (345–425)	1.7 (1.6–1.9)	0.51 (0.39–0.67)	23.4 (17.9–30.5)	124 805 (112 377–138 463)	207.4 (186.7–230.1)
Southern Latin America	34 021 (30 754–37 110)	52.1 (47.1–56.8)	2.54 (2.38–2.74)	38.9 (36.4–41.9)	626 (513–761)	12.5 (10.2–15.2)	0.29 (0.23–0.36)	57.8 (46.5–72.0)	26 071 (23 187–28 951)	516.2 (459.1–573.3)
Central Europe, eastern Europe, and central Asia	97 153 (86 019–110 400)	23.4 (20.7–26.6)	27 14 (25 20–29 20)	65.3 (60.6–70.3)	17 025 (13 377–22 085)	60.4 (47.4–78.3)	3.02 (2.41–3.71)	107.1 (85.4–131.7)	31 483 (28 367–34 849)	85.2 (76.7–94.3)
Eastern Europe	46 126 (36 064–58 694)	21.8 (17.1–27.8)	17 18 (15 84–18 62)	81.2 (74.9–88.0)	1791 (1454–2219)	13.8 (11.2–17.1)	1.46 (1.15–1.83)	112.6 (88.5–141.5)	11 363 (9178–14 151)	54.8 (44.3–68.3)
Central Europe	26 325 (24 435–28 353)	22.8 (21.1–24.5)	4.79 (4.48–5.13)	41.4 (38.7–44.4)	795 (674–939)	14.2 (12.1–16.8)	0.54 (0.43–0.67)	96.7 (76.9–119.7)	17 366 (15 787–19 073)	134.3 (122.1–147.5)
Central Asia	24 702 (20 925–29 866)	28.0 (23.7–33.8)	5.17 (4.77–5.59)	58.5 (54.1–63.3)	14 439 (10 821–19 609)	149.7 (112.2–203.3)	1.02 (0.81–1.24)	105.7 (84.0–128.2)	2753 (2488–3027)	82.9 (74.9–91.2)
Latin America and Caribbean	160 842 (150 906–170 365)	27.9 (26.2–29.5)	23 60 (22 05–25 23)	40.9 (38.2–43.8)	21 838 (19 982–24 428)	44.0 (40.3–49.2)	4.71 (3.82–5.70)	94.9 (77.0–114.8)	89 805 (81 557–97 556)	326.2 (296.2–354.3)
Central	43 191 (40 602–46 405)	17.0 (15.9–18.2)	5.30 (4.89–5.75)	20.8 (19.2–22.6)	9162 (8326–10 403)	40.1 (36.4–45.5)	1.32 (1.06–1.64)	57.8 (46.4–71.7)	19 219 (17 262–21 205)	175.3 (157.5–193.5)
Andean Latin America	28 653 (24 397–32 571)	47.9 (40.7–54.4)	3.76 (3.50–4.03)	62.8 (58.4–67.4)	4813 (3939–5793)	72.2 (59.1–86.9)	0.77 (0.62–0.93)	115.5 (93.8–140.1)	17 032 (13 894–19 794)	636.5 (519.2–739.7)
Caribbean	16 895 (15 166–18 887)	36.9 (33.2–41.3)	2.81 (2.60–3.03)	61.4 (56.9–66.3)	3128 (2046–4702)	78.4 (51.3–117.9)	0.60 (0.48–0.74)	150.1 (119.3–185.9)	9871 (8822–10 866)	344.3 (307.6–378.9)
Tropical Latin America	71 338 (66 753–75 856)	33.0 (30.8–35.0)	11.74 (10.99–12.54)	54.2 (50.7–57.9)	4639 (4197–5173)	28.8 (26.1–32.1)	2.02 (1.64–2.44)	125.3 (101.8–151.5)	43 198 (39 301–46 840)	391.7 (356.3–424.7)
Southeast Asia, east Asia, and Oceania	380 060 (328 336–442 923)	18.2 (15.8–19.8)	75 11 (69 18–81 50)	36.1 (33.2–39.1)	60 156 (53 483–67 970)	48.9 (43.5–55.2)	14.82 (11.75–18.29)	120.4 (95.5–148.6)	214 284 (179 802–237 500)	190.3 (159.6–210.9)
East Asia	171 297 (148 361–203 061)	12.1 (10.5–14.3)	44 22 (40 74–48 08)	31.2 (28.7–33.9)	17 022 (14 554–19 437)	26.3 (22.5–30.1)	6.94 (5.43–8.64)	107.4 (84.0–133.6)	115 743 (97 715–137 327)	132.3 (111.7–157.0)
Southeast Asia	201 790 (170 920–218 582)	30.8 (26.1–33.4)	30 04 (27 56–32 83)	45.9 (42.1–50.1)	40 181 (34 696–46 626)	70.5 (60.8–81.8)	7.63 (6.10–9.41)	133.9 (107.0–165.0)	97 141 (80 361–107 598)	389.8 (322.4–431.7)

(Table 1 continues on next page)




**Table 1: Episodes and deaths attributable to lower respiratory infections in 2016, by location**

At the global level, the case fatality ratio due to lower respiratory infections decreased sharply among under 5s, from 2.33% (95% UI 2.12–2.55) in 1990, to 0.96% (0.87–1.06) in 2016. The countries with the highest case fatality ratios were western sub-Saharan Africa (Burkina



(Figure 1 continues on next page)



**Figure 1: Global distribution of LRI mortality**

Lower respiratory infection mortality rate per 100 000 people for all ages (A), children younger than 5 years (B), and elderly adults (>70 years; C), in 2016. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. Isl=Islands. FSM=Federated States of Micronesia. TLS=Timor-Leste.

For more on comparing changes in mortality see <http://ihmeuw.org/4gti>

Faso 4·11%, 95% UI 3·29–4·71; Chad 3·46%, 3·12–3·79) and eastern sub-Saharan Africa (Somalia 3·60%, 2·82–4·24), whereas the lowest occurred in the Balkan countries and a few high-income countries (Slovenia 0·015%, 0·014–0·016; Bosnia and Herzegovina 0·025%, 0·023–0·027%; and Croatia 0·027%, 0·024–0·029; figure 2).

Our analysis showed that, of the four aetiologies studied, pneumococcal pneumonia was the leading cause of lower respiratory infection morbidity and mortality globally and caused more deaths than all other aetiologies combined: it was responsible for 1189 937 deaths (95% UI 690 445–1 770 660) and 197·05 million episodes (112·83–287·64) in 2016 (table 2). RSV was the second leading aetiology of lower respiratory infection deaths overall (76 612, 95% UI 55 121–103 503) and 54% of lower respiratory infection deaths attributable to RSV occurred in children younger than 5 years (41 026, 22 922–65 851), similar to the number of under-5 lower respiratory infection deaths attributable to Hib (48 011, 13 404–88 744; table 2). Hib was not attributed to deaths or episodes in people older than 5 years. Influenza is more frequently associated with non-fatal lower respiratory infection episodes than with fatal episodes. It was responsible for the second fewest number of deaths but it was the


second most common aetiology among LRI episodes (39·1 million episodes, 95% UI 30·5–48·4; table 2). Hib was not attributed to deaths or episodes in people older than 5 years because of insufficient data in these age groups. Because of expanded coverage of Hib and pneumococcal conjugate vaccines, in children younger than 5 years lower respiratory infection mortality due to Hib decreased by 5·86% and LRI mortality due to pneumococcal pneumonia decreased by 7·24% worldwide, with variation in super-region depending on the introduction and coverage of the vaccine (figure 3).

Childhood wasting remains the leading risk factor for lower respiratory infection mortality among children younger than 5 years, responsible for 57·1% of lower respiratory infection deaths (95% UI 30·1–66·7) in 2016 (appendix p 65). However, between 2000, and 2016, a decomposition of the contribution of the leading risk factors for lower respiratory infection mortality among children younger than 5 years showed that the largest reduction in lower respiratory infection mortality was due to improvements in childhood wasting, which was responsible for a 10·3% decrease (146 000 fewer deaths than if the prevalence of wasting had remained at the same level as in 2000; figure 3). Prevalence of childhood wasting improved in most locations; the largest decreases



occurred in Algeria (where a 32·2% decrease in wasting prevalence from 2000 to 2016, resulted in 800 fewer deaths than if no decrease had occurred) and the Democratic Republic of the Congo (31·1% decrease, 10700 fewer deaths; appendix p 66). We found an exception in Madagascar, where a greater prevalence of wasting contributed to a 36·0% increase in deaths (4100 excess deaths; appendix p 66). The second leading risk factor contributing to the reduction of under-5 lower respiratory infection mortality was a reduction in household and solid fuel air pollution, which were responsible for a 9·6% global decrease in deaths (135 000 fewer deaths; appendix p 66). Despite this decrease, this shift coincided in many locations with an increased exposure to ambient particulate matter pollution, which was responsible for a 3·7% increase in under-5 lower respiratory infection mortality (figure 3). In several rapidly developing countries in south Asia (Bangladesh, India, and Nepal), reduced household pollution contributed to a decrease in lower respiratory infection mortality, but ambient particulate matter pollution contributed to an increase in lower respiratory infection mortality (figure 3; appendix p 66). The region as a whole reflected this (5·0% increase due to particulate matter pollution and 12·4% decrease due to reduced indoor air pollution), with large differences in Bangladesh (7·3% increase due to particulate matter pollution and 7·5% decrease due to indoor air pollution) and India (5% increase due to particulate air pollution and 13·4% decrease due to indoor air pollution).

Among the countries with the highest lower respiratory infection mortality rate, interventions to reduce childhood wasting prevalence, improve household and ambient particulate matter pollution, and expand antibiotic treatment could avert an under-5 death due to lower respiratory infection for every 4000 children treated (figure 4; appendix p 45). Specifically, for every 1576 children who improve their weight-for-height Z score to the global mean, one death due to lower respiratory infection could be averted (95% UI 1319–2117; figure 4). Household air pollution has the second lowest number needed to treat globally (2527 needed to treat to avert one death, 95% UI 1999–3410; figure 4). Despite the fact that antibiotic treatment improved in most locations, being responsible for a 1·94% global decrease in under-5 lower respiratory infection mortality between 2000, and 2016, 30·2% of lower respiratory infection deaths among children younger than 5 years were attributable to lack of antibiotic treatment (95% UI 14·4–43·8; appendix p 65), and appropriate antibiotic treatment could avert one under-5 death due to lower respiratory infection for every 3200 children with lower respiratory infection who are treated (95% UI 2000–7470; figure 4; appendix p 75). Although the pneumococcal conjugate vaccine prevented 52 000 under-5 lower respiratory infection deaths in 2016, the large remaining burden of pneumococcal pneumonia reflects the vaccine's low coverage in high-burden locations and the large attributable fraction of pneumococcal pneumonia in



**Figure 2: Fatality ratio and sociodemographic index for children younger than 5 years, 2016**

The black line shows a smoothed loess curve for the relationship between sociodemographic index and lower respiratory infection case fatality ratio.

nearly every geography. Although reducing non-exclusive breastfeeding and exposure to second-hand tobacco smoke are the least efficient interventions at the global level, they are more efficient than targeting stunting, underweight, and handwashing in central Europe, central Asia, east Asia, and Latin America and the Caribbean (figure 4).

## Discussion

### Summary of findings


Substantial progress has been made to reduce the global burden of lower respiratory infections. However, this reduction has not been equal across locations, has been driven by decreases in several primary risk factors, and the burden in elderly adults could be growing and requires attention.

Our results suggest that the case fatality ratio among children younger than 5 years decreases rapidly with increasing sociodemographic development. There are several possible explanations for this observation, including improved access to health care, decreased exposure to disease risk, improved nutrition, and possibly improved case management.<sup>21</sup> A key goal of the GAPPD was universal access to appropriate lower respiratory infection case management.<sup>3</sup> More than

	Deaths (95% UI)	Fatal attributable fraction (95% UI)	Deaths per 100 000 people (95% UI)	Millions of episodes (95% UI)	Incidence per 1000 people (95% UI)
<b>All ages</b>					
<i>Streptococcus pneumoniae</i>	118 9937 (690445–1770660)	50.05% (29.22–73.94)	16.1 (9.3–24.0)	197.05 (112.83–287.64)	26.7 (15.3–38.9)
Respiratory syncytial virus	76 612 (55121–103503)	3.22% (2.32–4.40)	1.0 (0.7–1.4)	24.83 (19.65–31.42)	3.4 (2.7–4.3)
<i>Haemophilus influenzae</i> type b	48 011 (13404–88744)	2.02% (0.57–3.70)	0.6 (0.2–1.2)	6.73 (1.73–13.55)	0.9 (0.2–1.8)
Influenza	58 193 (43953–74175)	2.45% (1.86–3.10)	0.8 (0.6–1.0)	39.14 (30.54–48.44)	5.3 (4.1–6.6)
<b>Children younger than 5 years</b>					
<i>Streptococcus pneumoniae</i>	341 029 (195289–493551)	52.25% (29.95–73.00)	54.0 (30.9–78.1)	44.69 (20.87–73.68)	70.7 (33.0–116.6)
Respiratory syncytial virus	41 026 (22922–65851)	6.29% (3.58–10.17)	6.5 (3.6–10.4)	10.74 (6.70–16.56)	17.0 (10.6–26.2)
<i>Haemophilus influenzae</i> type b	48 011 (13404–88744)	7.36% (2.06–13.63)	7.6 (2.1–14.0)	6.08 (1.39–13.72)	9.6 (2.2–21.7)
Influenza	8360 (4905–13806)	1.28% (0.77–2.09)	1.3 (0.8–2.2)	5.75 (3.42–9.34)	9.1 (5.4–14.8)
<b>Elderly adults (&gt;70 years)</b>					
<i>Streptococcus pneumoniae</i>	494 340 (209900–896430)	45.74% (19.50–82.10)	122.3 (51.9–221.7)	29.43 (11.34–57.02)	72.8 (28.1–141.0)
Respiratory syncytial virus	22 009 (15705–30787)	2.04% (1.46–2.82)	5.4 (3.9–7.6)	2.54 (1.98–3.15)	6.3 (4.9–7.8)
<i>Haemophilus influenzae</i> type b*	..	..	..	..	..
Influenza	24 803 (16704–34251)	2.29% (1.59–3.17)	6.1 (4.1–8.5)	6.37 (4.79–8.16)	15.8 (11.8–20.2)

UI=uncertainty interval. \**Haemophilus influenzae* type b was not attributed to deaths or episodes in people older than 5 years.


**Table 2: Global deaths, fatal attributable fraction, and episodes due to each LRI aetiology, 2016**



**Figure 3: Percent change in deaths in children younger than 5 years, 2000–16**

50% of lower respiratory infection deaths in 2016 were attributable to bacterial aetiologies. We found that antibiotic use has increased in most locations and contributed to a 1.94% decrease in under-5 lower

respiratory infection mortality. Since the global number needed to treat is relatively small (3200), increased access to appropriate antibiotics could be an efficient intervention in many countries. We estimate that



(Figure 4 continues on next page)



(Figure 4 continues on next page)





(Figure 4 continues on next page)




Figure 4: Number of children younger than 5 years needed to treat to prevent a death due to lower respiratory infection, 2016

increased antibiotic availability could still prevent 30·2% (95% UI 14·4–43·8) of lower respiratory infection deaths. However, appropriate antibiotic use remains challenging—in large part because of the absence of reliable clinical signs and symptoms that can accurately predict bacterial pneumonia<sup>22,23</sup>—and universal use of

antibiotics for lower respiratory infections could lead to antimicrobial resistance.<sup>24</sup> Although interventions to expand judicious antibiotic use and improve diagnostic accuracy might help to mitigate this risk, these efforts must be accompanied by interventions to prevent cases of lower respiratory infection.

Pneumococcal pneumonia is by far the leading aetiology responsible for lower respiratory infection incidence and mortality in children and adults. There is increasing evidence that *S pneumoniae* might be a co-infection or a follow-up infection to viral infections.<sup>25</sup> However, given our counterfactual approach to aetiological attribution, it is possible to interpret our results as the expected reduction in lower respiratory infection burden in the total absence of an aetiology. Because our approach treats aetiological attribution independently, it is difficult to assess co-infections. The vaccine probe approach to aetiological attribution might miss indirect effects of the vaccine in protecting non-vaccinated people, a phenomenon that has been observed for pneumococcal conjugate vaccine. Despite this limitation, we observed a moderate reduction in lower respiratory infection mortality in children younger than 5 years after the introduction of pneumococcal conjugate vaccine in many countries, and the results suggest that a great deal of lower respiratory infection burden could be avertable if pneumococcal conjugate vaccine coverage was universal.

Risk factors for childhood undernutrition (stunting, wasting, and underweight) are among the leading risk factors for lower respiratory infection mortality in children younger than 5 years, and are strongly associated with poor health outcomes.<sup>17,26</sup> This association is probably due to impaired immunity caused by poor micronutrition and macronutrition. There are several reasons why many children in low-income countries, born underweight or not, tend to move further away from the global mean as they age. One reason might be a positive reinforcement loop that exists between infectious disease incidence, including lower respiratory infection and diarrhoea, which leads to poor physical growth, subsequently predisposing children to future episodes of infectious diseases.<sup>27–29</sup> Breaking these interactions has proved challenging, but some countries, such as Algeria, and the Democratic Republic of the Congo, have improved more than others with respect to childhood nutrition. This success might be due in part to improved maternal education, prenatal care, and interventions that target mothers and children.<sup>30–32</sup> Because lower respiratory infections can predispose (through undernutrition) or be concurrent with other underlying causes of death, such as HIV, there could be an even greater burden of the disease since the GBD attributes each death to only one underlying cause, which is consistent with the core principle of ICD codes reflecting the condition responsible for the causal pathway that ends in mortality.<sup>1,20</sup>

Exposure to indoor household solid fuel use and ambient particulate matter—the two key components of air pollution—varies widely, and they might be trending in opposite directions.<sup>33</sup> As countries develop in sociodemographic index, indoor air pollution tends

to decrease as cooking shifts from biofuels to natural gas and electricity.<sup>34</sup> At the same time, rapid proliferation of cheap fossil-fuel-based energy has led to much greater exposure to ambient particulate matter pollution. This paradox is a challenge of development. Reducing exposure to both types of air pollution is likely to be an efficient means to reduce lower respiratory infection mortality among children younger than 5 years. These risk factors, while ubiquitous in prevalence, have small associations with lower respiratory infection risk.<sup>33,35–37</sup> Several studies have identified only small effects, if any, of household air pollution on lower respiratory infection risk, and trials investigating indoor air pollution interventions have not shown major reductions in lower respiratory infection incidence.<sup>38–40</sup> Even if the improvements in lower respiratory infection mortality are lower than we estimated, improving air quality is a worthwhile goal for cognitive development, asthma, and other respiratory and cardiac outcomes.<sup>33</sup>

Our results suggest that nearly three-quarters of lower respiratory infection deaths occurred in older children and adults, with a particularly high burden in adults older than 70 years. Mortality rates in adults older than 70 years have remained remarkably consistent in most regions of the world since 1990, while the population of elderly adults has increased globally; there are twice as many adults older than 70 years in 2016, compared with 1990. Much of the global initiative to reduce the lower respiratory infection burden has been focused in children younger than 5 years, but our results suggest a growing need to expand this focus to include elderly populations. Further exploration of the effect of comorbidities and other risk factors that put older adults at risk of lower respiratory infection should be investigated, and exploration of the effect of pneumococcal conjugate vaccine in elderly populations in low-income and middle-income countries LMICs is warranted.

### Comparison with other estimates

The GBD 2016 estimates of lower respiratory infection mortality in children younger than 5 years in 2015 (700 554, 95% UI 635 081–767 610) were nearly identical to the estimates produced for GBD 2015 in the same year (703 918, 651 385–763 039; appendix p 32). However, the number of lower respiratory infection deaths among people of all ages in 2015 (2 388 748, 95% UI 2 157 662–2 520 283) was smaller than the number of deaths estimated for GBD 2015 (2 736 714, 2 500 318–2 860 843; appendix p 33).<sup>5</sup> This discrepancy is partly due to changes in the data sources used for lower respiratory infection mortality modelling. Notably, in India, reliable Sample Registration System data covering all states were introduced for GBD 2016. Moreover, a new process introduced in GBD 2016 to maintain consistency in estimates between cognitive diseases in elderly adults,

such as Alzheimer's disease and Parkinson's disease, re-distributed more lower respiratory infection deaths in age groups of adults older than 65 years to those causes of death than previously.

Our estimates of lower respiratory infection mortality in children younger than 5 years differ from those produced by the WHO Department of Evidence, Information and Research, and the Maternal and Child Epidemiology Estimation (MCEE) group, which estimates deaths due to pneumonia. The GBD 2016 estimates for under-5 mortality due to pneumonia in 2016 (700 554, 95% UI 635 081–767 610) are lower than those from the MCEE (920 136).<sup>41,42</sup> The source of much of this discrepancy is due to differences in the number of deaths in the two highest burden countries, India and Nigeria, where differences arise from input data and modelling approach (appendix pp 36–38). Our estimates of the number of lower respiratory infection episodes among children under-5 in 2010 (74130000, 95% UI 60610000–89700000)<sup>43</sup> are about half that of the numbers estimated by the MCEE group (120400000, 60800000–277000000) but with overlap in the 95% uncertainty intervals (appendix p 40). The estimates produced by the MCEE are informed by the incidence of pneumonia in 35 cohort studies, which informed an overall incidence of pneumonia that was related to the prevalence of five risk factors for pneumonia to estimate country-level incidence.<sup>44</sup> Although there is overlap in the risk factors used in both studies, GBD 2016 used more than 30 000 datapoints from more than 700 sources to produce internally consistent estimates of lower respiratory infection incidence, prevalence, and mortality.

Estimates for the aetiologies of lower respiratory infection also differ from other recently published estimates. Shi and colleagues<sup>45</sup> used a modelling strategy to estimate RSV incidence using 76 studies and several different approaches to defining a case fatality ratio. They estimated 59 600 (95% UI 48 000–74 500) deaths due to RSV among children younger than 5 years in 2015, and potentially as many as 118 200 (94 600–149 400), depending on model assumptions. By contrast, we estimated 41 000 deaths (95% UI 22 900–65 900) in 2016, with overlap in the uncertainty intervals. Iuliano and colleagues<sup>46</sup> estimated between 291 200 and 645 800 deaths associated with influenza among people of all ages in 2015, much higher than the GBD 2016 estimate of 58 200 (44 000–74 200). Although there are several differences in the approach to make these estimates, a major difference is the definition of an influenza death. In GBD 2016, we report the number of lower respiratory infection deaths attributable to influenza, whereas Iuliano and colleagues reported the number of respiratory deaths associated with influenza.<sup>46</sup>

#### Data limitations

Our estimates of lower respiratory infection burden are limited by data availability. In particular, the regions of the world with the highest lower respiratory infection

morbidity and mortality tend to be the places with the poorest data coverage, particularly for lower respiratory infection mortality and aetiological attribution. A detailed analysis done for GBD 2016 found that nearly all countries in Africa had poor vital record data, as measured by indices such as completeness and detail,<sup>1</sup> with only Egypt receiving a 3/5 grade (where 1 is worst and 5 is best, and 3/5 was the best grade received). Better surveillance systems, including standard reporting mechanisms and case definitions, in Africa and south and southeast Asia would substantially reduce a major source of uncertainty in the lower respiratory infection mortality estimates.<sup>47</sup> The predictive modelling approaches used in GBD 2016 rely on covariates and shared information across space and time to fill in these areas and the data gaps. Uncertainty is carried through each step of the lower respiratory infection modelling process and is represented in the uncertainty intervals for the results.

In recent years, PCR has become the gold standard for respiratory pathogen detection. However, even with the improved sensitivity of PCR diagnostic techniques, data about lower respiratory infection aetiologies remain sparse, partly because of challenges in obtaining appropriate samples from the site of infection, detection in healthy individuals, and relatively few data about aetiologies in adults.<sup>48,49</sup> Because of an absence of data in older children and adults, we assumed that the relationship between RSV and influenza and lower respiratory infections are the same in children younger than 5 years and in adults, which might not be true. Each iteration of the GBD study adds additional data that were either previously unidentified or have been published since the previous study, and GBD 2016 had an increase of 38% in available data for RSV and 20% more for influenza. Additionally, the relationship between disease severity, disease mortality, and aetiological attribution has not been well characterised for all pathogens and settings. Additional studies on lower respiratory infection aetiologies, including those in adults, which give detailed information on diagnostics, sample site, illness severity and co-infections, and with more discrete age ranges, are needed.

#### Next steps

The GBD study will be updated annually, with the most recent results superseding previous results. This approach provides a unique opportunity to be readily adaptable to changes in methods, to incorporate new or previously unidentified data sources, and to be timely with estimates of mortality and morbidity due to lower respiratory infection. Lower respiratory infections can be frequently associated with sepsis, which has not yet been estimated for the GBD. Recommended treatment for bacterial lower respiratory infections, with or without sepsis, is antibiotic therapy. Antimicrobial resistance is becoming more widely recognised as a leading global



health threat, and antimicrobial resistant will be quantified.

There might be substantial subnational variation in the burden of lower respiratory infection within countries. For example, an analysis of GBD 2016 focusing on India<sup>50</sup> found a seven-fold variation in lower respiratory infection mortality between states. To further investigate such variation, work to estimate the burden of lower respiratory infection at very fine spatial resolutions, similar to estimates of malaria and under-5 mortality,<sup>51,52</sup> will provide detailed evidence to guide policy at the local level and direct interventions to where they could affect the most change. This type of precision public health requires strong surveillance systems, sophisticated analytical approaches, and the capacity to act on the results.<sup>53</sup>

## Conclusions

Despite noteworthy decreases in the number of deaths due to lower respiratory infections since 2000, there remains an urgent need to accelerate efforts to reduce the burden of disease in the most susceptible populations, particularly those with high prevalence of childhood undernutrition, exposure to air pollution, and poor access to health care. The GBD study provides a comprehensive, comparable, scientific set of estimates for the burden of lower respiratory infections and these estimates provide both a description of the epidemiology of the disease and a potential roadmap for continuing to reduce the burden of the disease.

## GBD 2016 Lower Respiratory Infections Collaborators

Christopher Troeger, Brigitte F Blacker, Ibrahim A Khalil, Puja C Rao, Shujin Cao, Stephanie R M Zimsen, Sam Albertson, Jeffrey D Stanaway, Aniruddha Deshpande, Tamer Farag, Mohammad H Forouzanfar, Zegeye Abebe, Ifedayo Morayo O Adetifa, Tara Ballav Adhikari, Mohammed Akibu, Faris Hasan Al Lami, Ayman Al-Eyadhy, Nelson Alvis-Guzman, Azmeraw T Amare, Yaw Ampem Amoako, Carl Abelardo T Antonio, Olatunde Aremu, Ephrem Tsegay Asfaw, Solomon Weldegebreel Asgedom, Tesfay Mehari Atey, Engi Farouk Attia, Euripide Frinel G Arthur Avokpaho, Henok Tadesse Ayele, Tambe Bertrand Ayuk, Kalpana Balakrishnan, Aleksandra Barac, Quisque Bassat, Masoud Behzadifar, Meysam Behzadifar, Soumyadeep Bhaumik, Zulfiqar A Bhutta, Ali Bijani, Michael Brauer, Alexandria Brown, Paulo A M Camargos, Carlos A Castañeda-Orjuela, Danny Colombara, Sara Conti, Abel Fekadu Dadi, Lalit Dandona, Rakhi Dandona, Huyen Phuc Do, Eleonora Dubljanin, Dumessa Edessa, Hajer Elkout, Aman Yesuf Endries, Daniel Obadare Fijabi, Kyle J Foreman, Nancy Fullman, Alberto L Garcia-Basteiro, Bradford D Gessner, Peter W Gething, Rahul Gupta, Tarun Gupta, Gessesew Bugssa Hailu, Hamid Yimam Hassen, Mohammad T Hedayati, Mohsen Heidari, Desalegn Tsegaw Hibstu, Nobuyuki Horita, Olayinka S Ilesanmi, Mihajlo B Jakovljevic, Amr A Jamal, Amaha Kahsay, Amir Kasaecian, Dessalegn Haile Kassa, Yousef Saleh Khader, Ejaz Ahmad Khan, Md Nuruzzaman Khan, Young-Ho Khang, Yun Jin Kim, Niranjan Kisson, Luke D Knibbs, Sonali Kochhar, Parvaiz A Koul, G Anil Kumar, Rakesh Lodha, Hassan Magdy Abd El Razek, Deborah Carvalho Malta, Joseph L Mathew, Desalegn Tadesse Mengistu, Haftay Berhane Mezgebe, Karzan Abdulmuhsin Mohammad, Mohammed A Mohammed, Fatemeh Momeniha, Srinivas Murthy, Cuong Tat Nguyen, Katie R Nielsen, Dina Nur Anggraini Ningrum, Yirga Legesse Nirayo, Eyal Oren, Justin R Ortiz, Mahesh PA, Maarten J Postma, Mostafa Qorbani, Reginald Quansah, Rajesh Kumar Rai, Saleem M Rana, Chhabhi Lal Ranabhat, Sarah E Ray, Mohammad Sadegh Rezaei,

George Mugambage Ruhago, Saeid Safiri, Joshua A Salomon, Benn Sartorius, Miloje Savic, Monika Sawhney, Jun She, Aziz Sheikh, Mekonnen Sisay Shiferaw, Mika Shigematsu, Jasvinder A Singh, Ranjani Somayaji, Muawiyah Babale Sufiyan, Getachew Redae Taffere, Mohamad-Hani Temsah, Matthew J Thompson, Ruoyan Tobe-Gai, Roman Topor-Madry, Bach Xuan Tran, Tung Thanh Tran, Kald Beshir Tuem, Kingsley Nnanna Ukwaja, Stein Emil Vollset, Judd I Watson, Fitsum Weldegebreel, Andrea Werdecker, T Eoin West, Naohiro Yonemoto, Maysaa El Sayed Zaki, Lei Zhou, Sanjay Zodpey, Theo Vos, Stephen S Lim, Mohsen Naghavi, Christopher J L Murray, Ali H Mokdad, Simon I Hay\*, and Robert C Reiner Jr\*†.

\*Joint last authors. †Corresponding author.

## Affiliations

Institute for Health Metrics and Evaluation (C Troeger MPH, B Blacker MPH, I A Khalil MD, P C Rao MPH, J Cao, S R M Zimsen MA, S Albertson, A Deshpande MPH, T Farag PhD, M H Forouzanfar MD, Prof M Brauer ScD, A Brown MA, D Colombara PhD, Prof L Dandona MD, Prof R Dandona PhD, K J Foreman PhD, N Fullman MPH, S E Ray BS, J D Stanaway PhD, Prof S Vollset DrPH, Prof T Vos PhD, Prof M Naghavi PhD, Prof S S Lim PhD, Prof A H Mokdad PhD, Prof C J L Murray DPhil, Prof S I Hay DSc, R C Reiner PhD), Center for Health Trends and Forecasts (Prof M B Jakovljevic PhD), Department of Global Health (S Kochhar MD, K R Nielsen MD, J R Ortiz MD, J L Watson MD), Department of Medicine (E F Attia MD, R Somayaji MD, T E West MD), Department of Pediatrics (K R Nielsen MD), School of Public Health (Prof E Oren PhD), University of Washington, Seattle, WA, USA (Prof M J Thompson DPhil); University of Gondar, Gondar, Ethiopia (Z Abebe MS, A F Dadi MPH); London School of Hygiene & Tropical Medicine, London, UK (I M O Adetifa PhD); KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya (I M O Adetifa); Health Research (T B Adhikari MPH), Center for Social Science and Public Health Research Nepal, Lalitpur, Nepal; Faculty of Health Sciences, Unit for Health Promotion Research (T B Adhikari), University of Southern Denmark, Esbjerg, Denmark; Debre Berhan University, Debre Berhan, Ethiopia (M Akibu MS); Community and Family Medicine (F H Al Lami PhD), Department of Pharmacy (H B Mezgebe MS), Academy of Medical Science, Baghdad, Iraq; King Saud University, Riyadh, Saudi Arabia (A Al-Eyadhy MD, A A Jamal MD, M Temsah MD); King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia (A Al-Eyadhy); Research Group in Health Economics (Prof N Alvis-Guzman PhD), University of Cartagena, Cartagena, Colombia; South Australian Health and Medical Research Institute, Sansom Institute (A T Amare MPH), University of South Australia, Adelaide, SA, Australia; Bahir Dar University, Bahir Dar, Ethiopia (A T Amare); Komfo Anokye Teaching Hospital, Kumasi, Ghana (Y A Amoako MD); Department of Health Policy and Administration, College of Public Health (C A T Antonio MD), University of the Philippines Manila, Manila, Philippines; Birmingham City, University Department of Public Health and Therapies, Birmingham, UK (O Aremu PhD); Biomedical Sciences Division (D T Mengistu MS), College of Health Sciences, Institute of Biomedical Sciences, Medical Microbiology and Immunology Unit (E T Asfaw MS), Department of Environmental Health and Behavioral Science (G R Taffere PhD), Mekelle University, Mekelle, Ethiopia (S W Asgedom MS, T Atey MS, G B Hailu MSc, A Kahsay MPH, Y L Nirayo MSc, K B Tuem MS); Institut de Recherche Clinique du Bénin (IRCB), Cotonou, Benin (E F G A Avokpaho MPH); Laboratoire d'Etudes et de Recherche-Action en Santé (LERAS Afrique), Parakou, Benin (E F G A Avokpaho); Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada (H Ayele PhD); Department of Public Health, Dilla University, Dilla, Ethiopia (H Ayele); Centre for Food and Nutrition Research, Institute of Medical Research and Plant Medicinal Studies-Cameroon (IMPM), Yaounde, Cameroon (T B Ayuk MPH); University of South Africa, Pretoria, South Africa (T B Ayuk); Department of Environmental Health Engineering, Sri Ramachandra University, Chennai, India (K Balakrishnan PhD); Faculty of Medicine (A Barac PhD), Institute of Microbiology and Immunology, Faculty of Medicine (E Dubljanin PhD), University of Belgrade, Belgrade, Serbia; Barcelona Institute for Global Health

- (ISGlobal), Universitat de Barcelona, Barcelona, Spain (Prof Q Bassat MD); Manhiça Health Research Center, Manhiça, Mozambique (Prof Q Bassat, A L Garcia-Basteiro MSc); Lorestan University of Medical Sciences, Khorramabad, Iran (M Behzadifar MS, M Behzadifar MS); The George Institute for Global Health, New Delhi, India (S Bhaumik MSc); Centre for Global Child Health, The Hospital for Sick Children, Toronto, ON, Canada (Z A Bhutta PhD); Centre of Excellence in Women and Child Health, Aga Khan University, Karachi, Pakistan (Z A Bhutta); Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran (A Bijani PhD); University of British Columbia, Vancouver, BC, Canada (Prof M Brauer ScD, Prof N Kisson MD, S Murthy MD); Federal University of Minas Gerais, Belo Horizonte, Brazil (Prof P A M Camargos PhD); Colombian National Health Observatory, National Institute of Health, Bogota, Colombia (C A Castañeda-Orjuela MSc); Epidemiology and Public Health Evaluation Group, Public Health Department, National University of Colombia, Bogota, Colombia (C A Castañeda-Orjuela); University of Milano Bicocca, Monza, Italy (S Conti PhD); Flinders University, Adelaide, NSW, Australia (A F Dadi MPH); Public Health Foundation of India, Gurugram, India (Prof L Dandona MD, Prof R Dandona PhD, G Kumar PhD, Prof S Zodpey PhD); Institute for Global Health Innovations, Duy Tan University, Da Nang, Vietnam (H P Do MSc, C T Nguyen MSc, T T Tran MSc); School of Pharmacy (D Edessa MS), Haramaya University, Harar, Ethiopia (M S Shiferaw MS, F Weldegebreab MS); Community and Family Medicine, Tripoli University, Tripoli, Libya (H Elkout PhD); World Health Organization, Tripoli, Libya (H Elkout); Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia (A Y Endries MPH); Heller Graduate School, Brandeis University, Waltham, MA, USA (D O Fijabi MBBS); School of Public Health, University of Memphis, Memphis, TN, USA (D O Fijabi); Imperial College London, London, UK (K J Foreman PhD); Barcelona Institute for Global Health, Barcelona, Spain (A L Garcia-Basteiro MSc); Agence de Medecine Preventive, Paris, France (B D Gessner MD); Nuffield Department of Medicine, Big Data Institute, University of Oxford, Oxford, UK (P W Gething PhD); West Virginia Bureau for Public Health, Charleston, WV, USA (R Gupta MD); Indian Institute of Technology Kanpur, Kanpur, India (Prof T Gupta DSc); Kile Awlaelo Health and Demographic Surveillance System, Mekelle, Ethiopia (G B Hailu MSc); Mizan Tepi University, Mizan Teferi, Ethiopia (H Y Hassen MPH); Department of Medical Mycology and Parasitology, School of Medicine (Prof M T Hedayati PhD), Invasive Fungi Research Center (Prof M T Hedayati), Mazandaran University of Medical Sciences, Sari, Iran (M Rezaei MD); Faculty of Health, Hormozgan University of Medical Sciences, Bandar Abbas, Iran (M Heidari PhD); Department of Reproductive Health (D T Hibstu MPH), Hawassa University, Hawassa, Ethiopia; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan (N Horita MD); Foundation for National Institutes of Health, Bethesda, MD, USA (N Horita); National Public Health Institute, Monrovia, Liberia (O S Ilesanmi MD); Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia (Prof M B Jakovljevic PhD); Hematologic Malignancies Research Center (A Kasaeian PhD), Hematology-Oncology and Stem Cell Transplantation Research Center (A Kasaeian), Tehran University of Medical Sciences, Tehran, Iran; Debre Markos University, Debre Markos, Ethiopia (D H Kassa MS); Department of Community Medicine, Public Health and Family Medicine, Jordan University of Science and Technology, Irbid, Jordan (Prof Y S Khader ScD); Health Services Academy, Islamabad, Pakistan (E A Khan MD); The University of Newcastle, Newcastle, NSW, Australia (M N Khan MS); Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh (M N Khan); Department of Health Policy and Management (Prof Y Khang MD), Seoul National University College of Medicine, Seoul, South Korea; Institute of Health Policy and Management (Prof Y Khang), Seoul National University Medical Center, Seoul, South Korea; School of Medicine, Xiamen University Malaysia Campus, Sepang, Malaysia (Y Kim PhD); School of Public Health, University of Queensland, Brisbane, QLD, Australia (L D Knibbs PhD); Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands (S Kochhar MD); Department of Internal and Pulmonary Medicine, Sheri Kashmir Institute of Medical Sciences, Srinagar, India (Prof P A Koul MD); All India Institute of Medical Sciences, New Delhi, India (R Lodha MD); Damietta University, Damietta, Egypt (H Magdy Abd El Razek MBBCH); Universidade Federal de Minas Gerais, Belo Horizonte, Brazil (Prof D C Malta PhD); Postgraduate Institute of Medical Education and Research, Chandigarh, India (Prof J L Mathew MD); Salahaddin University, Erbil, Iraq (K A Mohammad PhD); Ishik University, Erbil, Iraq (K A Mohammad); Jigjiga University, Jigjiga, Ethiopia (M A Mohammed MS); University of Sydney, Sydney, NSW, Australia (M A Mohammed); School of Public Health, Department of Environmental Health Engineering (F Momeniha MS), Iran University of Medical Sciences, Tehran, Iran; Department of Public Health, Semarang State University, Semarang City, Indonesia (D N A Ningrum MPH); Graduate Institute of Biomedical Informatics, College of Medical Science and Technology (D N A Ningrum), Taipei Medical University, Taipei City, Taiwan; Division of Epidemiology & Biostatistics, Graduate School of Public Health (Prof E Oren PhD), San Diego State University, San Diego, CA, USA; Center of Vaccine Development (J R Ortiz MD), University of Maryland, Baltimore, MD, USA; Department of Pulmonary Medicine, Jagadguru Sri Shivarathreeswara University, Mysore, India (Prof M PA DNB); University Medical Center Groningen, Groningen, Netherlands (Prof M J Postma PhD); University of Groningen, (Prof M J Postma); Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran (M Qorbani PhD); University of Ghana, Accra, Ghana (R Quansah PhD); Noguchi Memorial Institute of Medical Research, Accra, Ghana (R Quansah); Society for Health and Demographic Surveillance, Suri, India (R Rai MPH); University of Göttingen, Göttingen, Germany (R Rai); Contech School of Public Health, Lahore, Pakistan (Prof S M Rana PhD); Contech International Health Consultants, Lahore, Pakistan (Prof S M Rana); Institute for Poverty Alleviation and International Development, Yonsei University, Wonju, South Korea (C L Ranabhat PhD); Health Science Foundation and Study Center, Kathmandu, Nepal (C L Ranabhat); Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania (G M Ruhago PhD); Managerial Epidemiology Research Center, Department of Public Health, School of Nursing and Midwifery (S Safiri PhD), Maragheh University of Medical Sciences, Maragheh, Iran; Center for Health Policy & Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA (J A Salomon PhD); Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa (Prof B Sartorius PhD); UKZN Gastrointestinal Cancer Research Centre, South African Medical Research Council, Durban, South Africa (Prof B Sartorius); GSK Biologicals, Wavre, Belgium (M Savic PhD); Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA (M Sawhney PhD); Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China (J She MD); The University of Edinburgh, Edinburgh, UK (Prof A Sheikh MD); Division of General Internal Medicine and Primary Care, Harvard University, Boston, MA, USA (Prof A Sheikh); National Institute of Infectious Diseases, Tokyo, Japan (M Shigematsu PhD); Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA (J A Singh MD); University of Calgary, Calgary, AB, Canada (R Somayaji MD); Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria (M B Sufiyan MBA); College of Medicine, Alfaisal University, Riyadh, Saudi Arabia (M Tamsah MD); Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan (R Tobe-Gai PhD); Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland (R Topor-Madry PhD); Faculty of Health Sciences, Wrocław Medical University, Wrocław, Poland (R Topor-Madry); Hanoi Medical University, Hanoi, Vietnam (B X Tran PhD); Department of Internal Medicine, Federal Teaching Hospital, Abakaliki, Nigeria (K N Ukwaja MD); Department of Demographic Change and Ageing, Federal Institute for Population Research, Wiesbaden, Germany (A Werdecker PhD); Department of Biostatistics, School of Public Health, Kyoto University, Kyoto, Japan (N Yonemoto MPH); Faculty of Medicine, Mansoura University, Mansoura, Egypt (Prof M El Sayed Zaki PhD); Jinan Central Hospital, Jinan, China (L Zhou MD).

## Contributors

CT and BFB prepared the first draft. CT constructed the figures and tables. SIH, RCR, and MHF provided overall guidance. PCR and BFB managed the project. CT, BFB, and IAK finalised the manuscript on the basis of comments from other authors and reviewer feedback. All other authors provided data or developed models for indicators, reviewed results, initiated modelling infrastructure, or reviewed and contributed to the paper.

## Declaration of interests

CATA reports grants and personal fees from Johnson & Johnson (Philippines) Inc, outside the submitted work. BDG reports employment from Pfizer Vaccines during the conduct of the study, and reports grants from GSK, Merck, Pfizer, and Sanofi Pasteur, outside the submitted work. MBJ reports grants from Ministry of Education Science and Technological Development of the Republic of Serbia (grant OI 175014) during the conduct of the study. MJP reports grants and personal fees from AbbVie, Sigma Tau, MSD, GSK, Pfizer, Asca, Boehringer Ingelheim, Novavax, and Ingress Health, grants from Bayer, BMS, Astra Zeneca, Sanofi, and ARTEG, and personal fees from Astellas, Mapi, OptumInsight, Novartis, Swedish Orphan, Innoval, Jansen, Intercept, and Pharmarit; holds 2% of stocks in Ingress Health (a health economics consultancy); and advises two pharmacoeconomics spin-off companies from the University of Groningen. MSav reports employment at GSK Biologicals SA, Wavre, Belgium, from Feb 1, 2018. JAS reports grants from Takeda and Savient, and personal fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon, Allergan, UBM LLC, WebMD, and The American College of Rheumatology. Outside the submitted work, JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc (a 501c3 entity), and is a steering committee member of OMERACT, which receives funding from 36 pharmaceutical companies. The other authors declare no competing interests.

## Acknowledgments

ABa is funded by the Project of Ministry of Education, Science and Technology of the Republic of Serbia (number III45005). SMR would like to acknowledge Contech School of Public Health management for their cooperation. RS reports research funding from the Cystic Fibrosis Foundation, Cystic Fibrosis Canada, Alberta Innovates, and the Canadian Institutes of Health Research.

## References

- GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; **390**: 1151–210.
- UNICEF. One is too many: ending child deaths from pneumonia and diarrhoea. New York: United Nations International Children's Emergency Fund, 2016.
- WHO, UNICEF. End preventable deaths: global action plan for prevention and control of pneumonia and diarrhoea. Geneva: World Health Organization, 2013.
- UN Department of Economic and Social Affairs. Transforming our world: the 2030 agenda for sustainable development. 2015. <https://sustainabledevelopment.un.org/post2015/transformingourworld> (accessed Oct 23, 2016).
- GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis* 2017; **17**: 1133–61.
- Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *Lancet* 2016; **388**: e19–23.
- Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr* 2012; **10**: 1.
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; **390**: 1211–59.
- Feikin DR, Scott JAG, Gessner BD. Use of vaccines as probes to define disease burden. *Lancet* 2014; **383**: 1762–70.
- O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet* 2009; **374**: 893–902.
- Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by *Haemophilus influenzae* type b in children younger than 5 years: global estimates. *Lancet* 2009; **374**: 903–11.
- Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing *Haemophilus influenzae* type B infections. *Cochrane Database Syst Rev* 2007; **4**: CD001729.
- Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. *Cochrane Database Syst Rev* 2009; **4**: CD004977.
- Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. *J Glob Health* 2015; **5**: 010408.
- Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. *Am J Epidemiol* 1974; **99**: 325–32.
- GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; **388**: 1659–724.
- GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; **390**: 1345–422.
- Rothman K, Greenland S, Lash T. Modern epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008.
- Das Gupta P. Standardization and decomposition of rates: a user's manual. Washington, DC: US Department of Commerce, Economics and Statistics Administration, Bureau of the Census, 1993.
- GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; **390**: 1084–150.
- Duke T, Wandt F, Jonathan M, et al. Improved oxygen systems for childhood pneumonia: a multihospital effectiveness study in Papua New Guinea. *Lancet* 2008; **372**: 1328–33.
- Hazir T, Begum K, El Arifeen S, et al. Measuring coverage in MNCH: a prospective validation study in Pakistan and Bangladesh on measuring correct treatment of childhood pneumonia. *PLoS Med* 2013; **10**: e1001422.
- Rambaud-Althaus C, Althaus F, Genton B, D'Acremont V. Clinical features for diagnosis of pneumonia in children younger than 5 years: a systematic review and meta-analysis. *Lancet Infect Dis* 2015; **15**: 439–50.
- Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant *Streptococcus pneumoniae* in pre- and post-conjugate vaccine eras: a United States perspective. *Clin Microbiol Rev* 2016; **29**: 525–52.
- Malosh RE, Martin ET, Ortiz JR, Monto AS. The risk of lower respiratory tract infection following influenza virus infection: a systematic and narrative review. *Vaccine* 2018; **36**: 141–47.
- Olofin I, McDonald CM, Ezzati M, et al. Associations of suboptimal growth with all-cause and cause-specific mortality in children under five years: a pooled analysis of ten prospective studies. *PLoS One* 2013; **8**: e64636.
- Colombara DV, Khalil IA-M, Rao PC, et al. Chronic health consequences of acute enteric infections in the developing world. *Am J Gastroenterol Suppl* 2016; **3**: 4–11.
- Salam RA, Das JK, Bhutta ZA. Current issues and priorities in childhood nutrition, growth, and infections. *J Nutr* 2015; **145**: 1116S–22.
- Ibrahim MK, Zambruni M, Melby CL, Melby PC. Impact of childhood malnutrition on host defense and infection. *Clin Microbiol Rev* 2017; **30**: 919–71.
- Akombi BJ, Agho KE, Hall JJ, Wali N, Renzaho AMN, Merom D. Stunting, wasting and underweight in sub-Saharan Africa: a systematic review. *Int J Environ Res Public Health* 2017; published online Aug 1. DOI:10.3390/ijerph14080863.

- 31 Duggan MB. Prevention of childhood malnutrition: immensity of the challenge and variety of strategies. *Paediatr Int Child Health* 2014; **34**: 271–78.
- 32 Imdad A, Sadiq K, Bhutta ZA. Evidence-based prevention of childhood malnutrition. *Curr Opin Clin Nutr Metab Care* 2011; **14**: 276–85.
- 33 Burnett RT, Pope CA, Ezzati M, et al. An integrated risk function for estimating the global burden of disease attributable to ambient fine particulate matter exposure. *Environ Health Perspect* 2014; **122**: 397–403.
- 34 Kurmi OP, Lam KBH, Ayres JG. Indoor air pollution and the lung in low- and medium-income countries. *Eur Respir J* 2012; **40**: 239–54.
- 35 Dherani M, Pope D, Mascarenhas M, Smith KR, Weber M, Bruce N. Indoor air pollution from unprocessed solid fuel use and pneumonia risk in children aged under five years: a systematic review and meta-analysis. *Bull World Health Organ* 2008; **86**: 390–98C.
- 36 Nhung NTT, Amini H, Schindler C, et al. Short-term association between ambient air pollution and pneumonia in children: a systematic review and meta-analysis of time-series and case-crossover studies. *Environ Pollut* 1987 2017; **230**: 1000–08.
- 37 Mehta S, Shin H, Burnett R, North T, Cohen AJ. Ambient particulate air pollution and acute lower respiratory infections: a systematic review and implications for estimating the global burden of disease. *Air Qual Atmosphere Health* 2013; **6**: 69–83.
- 38 Quansah R, Semple S, Ochieng CA, et al. Effectiveness of interventions to reduce household air pollution and/or improve health in homes using solid fuel in low-and-middle income countries: a systematic review and meta-analysis. *Environ Int* 2017; **103**: 73–90.
- 39 Mortimer K, Ndamala CB, Naunje AW, et al. A cleaner burning biomass-fuelled cookstove intervention to prevent pneumonia in children under 5 years old in rural Malawi (the Cooking and Pneumonia Study): a cluster randomised controlled trial. *Lancet* 2017; **389**: 167–75.
- 40 Smith KR, McCracken JP, Weber MW, et al. Effect of reduction in household air pollution on childhood pneumonia in Guatemala (RESPIRE): a randomised controlled trial. *Lancet* 2011; **378**: 1717–26.
- 41 Johns Hopkins Bloomberg School of Public Health. Maternal child epidemiology estimation. <https://www.jhsph.edu/research/centers-and-institutes/institute-for-international-programs/current-projects/maternal-child-epidemiology-estimation/> (accessed Oct 23, 2017).
- 42 WHO. Estimates for 2000–2015. <http://apps.who.int/gho/data/view.main.CM1002015WORLD-CH9?lang=en> (accessed June 25, 2018).
- 43 Walker CLF, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. *Lancet* 2013; **381**: 1405–16.
- 44 Rudan I, O'Brien KL, Nair H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. *J Glob Health* 2013; **3**: 010401.
- 45 Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* 2017; **390**: 946–58.
- 46 Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet* 2018; **391**: 1285–300.
- 47 Mikkelsen L, Phillips DE, AbouZahr C, et al. A global assessment of civil registration and vital statistics systems: monitoring data quality and progress. *Lancet* 2015; **386**: 1395–406.
- 48 Scott JAG, Brooks WA, Peiris JSM, Holtzman D, Mulholland EK. Pneumonia research to reduce childhood mortality in the developing world. *J Clin Invest* 2008; **118**: 1291–300.
- 49 Templeton KE, Scheltinga SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Claas EC. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. *Clin Infect Dis* 2005; **41**: 345–51.
- 50 India State-Level Disease Burden Initiative Collaborators. Nations within a nation: variations in epidemiological transition across the states of India, 1990–2016 in the Global Burden of Disease Study. *Lancet* 2017; **390**: 2437–60.
- 51 Gething PW, Casey DC, Weiss DJ, et al. Mapping *Plasmodium falciparum* mortality in Africa between 1990 and 2015. *N Engl J Med* 2016; **375**: 2435–45.
- 52 Golding N, Burstein R, Longbottom J, et al. Mapping under-5 and neonatal mortality in Africa, 2000–15: a baseline analysis for the Sustainable Development Goals. *Lancet* 2017; **390**: 2171–82.
- 53 Dowell SF, Blazes D, Desmond-Hellmann S. Four steps to precision public health. *Nature* 2016; **540**: 189.